Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
暂无分享,去创建一个
Ying Cheng | Y. Ba | Jianming Xu | Changping Wu | Yunpeng Liu | Jun Liang | R. Xu | Leizhen Zheng | S. Qin | G. Sun | Lei Chen | Jianwei Yang | Jin Li | Jingbo Wu | X. Ouyang | R. Zheng | J. Xiong | Y. Bai | Yan Yang | Liwei Wang | N. Xu | Zhehai Wang | Hao Yu | D. Luo | Wei Liu | Hong Guo | Xiaoyan Lin | J. Tong | Xin Wang | Hong-gang Zhang | Qiong Wang | Ningju Wang | Zhi-lu Fan | Piaoyang Sun | Li-wei Wang | Jianwei Yang
[1] Naotoshi Sugimoto,et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[2] C. Fuchs,et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.
[3] J. Maurel,et al. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study , 2013, Investigational New Drugs.
[4] Ying Cheng,et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Xing-Lin Chen,et al. Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis , 2013, PloS one.
[6] Z. Shao,et al. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy , 2013, Breast Cancer Research and Treatment.
[7] Y. Bang,et al. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival , 2013, Gastric Cancer.
[8] Jin Li,et al. Novel targeted agents for gastric cancer , 2012, Journal of Hematology & Oncology.
[9] M. Shah,et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Joon-Oh Park,et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Choi,et al. Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer , 2011, Cancer research and treatment : official journal of Korean Cancer Association.
[12] M. Shah,et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Y. Bang,et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[14] A. Jemal,et al. Global Cancer Statistics , 2011 .
[15] Y. Bang,et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer , 2010, Investigational New Drugs.
[16] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[17] S. Srinivas,et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] A. Norman,et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.
[19] E. Voest,et al. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. , 2007, The oncologist.